Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells
Open Access
- 1 February 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 95 (3) , 863-869
- https://doi.org/10.1182/blood.v95.3.863.003k12_863_869
Abstract
The development and evaluation of drugs to elevate fetal hemoglobin in the treatment of the genetic diseases of hemoglobin would be facilitated by the availability of reliable cell assays. We have used real-time, quantitative polymerase chain reaction (PCR) analyses of globin messenger RNA (mRNA) levels in a biphasic, erythropoietin-dependent primary culture system for human adult erythroid cells in order to assay compounds for their ability to modulate levels of adult (β) and fetal (γ) globin mRNA. Complementary DNA synthesized from total RNA extracted at timed intervals from aliquots of cells were assayed throughout the period that the culture was studied. γ-globin mRNA levels were found to be much lower (less than 1%) than β-globin mRNA levels. At concentrations of agents chosen for minimal effect on cell division, we find that the 3 drugs studied, 5-azacytidine (5μmol/L), hydroxyurea (40μmol/L), and butyric acid (0.5mmol/L), significantly increase γ-globin mRNA levels. Interestingly, hydroxyurea also had a small stimulatory effect on β-globin mRNA levels, while butyric acid caused a twofold inhibition of β-globin mRNA levels, and 5-azacytidine had little effect on β-globin mRNA levels. The net result of all 3 drugs was to increase the γ/(γ + β) mRNA ratios by threefold to fivefold. These data suggest that the mechanism is distinct for each drug. The profile of butyric-acid–induced changes on globin gene expression is also quite distinct from changes produced by trichostatin A, a known histone deacetylase inhibitor. Quantitative PCR analyses of human erythroid cells should prove useful for studying the mechanism(s) of action of known inducers of γ-globin and identifying new drug candidates.Keywords
This publication has 37 references indexed in Scilit:
- Fetal gene reactivationCurrent Opinion in Genetics & Development, 1998
- Pharmacological induction of foetal haemoglobin synthesis in sickle-cell disease.The Netherlands Journal of Medicine, 1997
- Real time quantitative PCR.Genome Research, 1996
- NOVEL TREATMENT OPTIONS IN THE SEVERE β‐GLOBIN DISORDERSBritish Journal of Haematology, 1995
- A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin DisordersNew England Journal of Medicine, 1993
- Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]Blood, 1992
- Hematologic Responses of Patients with Sickle Cell Disease to Treatment with HydroxyureaNew England Journal of Medicine, 1990
- Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex.Proceedings of the National Academy of Sciences, 1983
- 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemiaBlood, 1983
- 5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β+ThalassemiaNew England Journal of Medicine, 1982